Key result
Concurrent therapies including probucol, carvedilol, dexrazoxane, and antioxidants are being studied to attenuate doxorubicin-induced cardiomyopathy while maintaining antitumor efficacy.
Population
Patients receiving doxorubicin for the treatment of cancer
Design
Review
Authors
Loading...
May inform nursing assessment of emerging cardioprotectants in doxorubicin recipients; leaves open randomized confirmation of net benefit.
This review highlights concurrent therapies such as carvedilol and dexrazoxane that may attenuate doxorubicin-induced cardiomyopathy, emphasizing the role of nurses in patient education and assessment.
Simpson et al. (2004) conducted a review in Doxorubicin-induced cardiomyopathy. Concurrent therapies (probucol, carvedilol, dexrazoxane, antioxidant nutrients) was evaluated. Concurrent therapies including probucol, carvedilol, dexrazoxane, and antioxidants are being studied to attenuate doxorubicin-induced cardiomyopathy while maintaining antitumor efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: